Home » Newsletters » BioWorld Science

BioWorld Science

March 12, 2003

View Archived Issues

Gemin X claims novel compounds for cancer, viral infections and autoimmune diseases

Novel antitumor ecteinascidins reported by Spanish research team

CV Therapeutics describes novel fatty acid oxidation inhibitors

New prostanoid EP4 receptor agonists and their use in osteoporosis

Bayer claims new series of thiazole-based anti-HSV agents

Novel antibacterial dimeric vancomycin derivatives claimed by Theravance

New MMP inhibitors for arthritis and other disorders discovered at Leo

Novel neuraminidase inhibitors in early development at BioCryst

Two series of PDE4 inhibitors identified by Merck researchers

Active Biotech reports on recent progress

Potential use of DX-88 in the treatment of hereditary angioedema

Good safety and efficacy for INS-37217 in the treatment of perennial allergic rhinitis

Improved management of malignant liver tumors with ferucarbotran-enhanced MRI

Sonazoid-enhanced ultrasound reported to improve the detection of liver metastases

Mepolizumab reported to inhibit eosinophil function in asthma and allergy

Antiallergic effects of CAT-213 in grass pollen-sensitive subjects

Telik offers progress report

NicOx reviews phase II data for AZD-3582

Velcade NDA granted priority review

Endovasc plans to file Liprostin IND for diabetic neuropathy

Viragen's natural interferon alfa approved in South Africa

Phase II results announced for ISA-247 in psoriasis

Enrollment completed in phase III trial of Aptosyn/Taxotere in NSCLC

Gilead's Hepsera approved for marketing in E.U. countries

Nippon Kayaku to seek marketing clearance for gusperimus in Europe

SMP-114 now in phase II development in Europe

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...